Pernicious anemia during peginterferon-alpha2b plus ribavirin therapy for chronic hepatitis C.
Musialik
Joanna
J
Petelenz
Michał
M
Błoñska-Fajfrowska
Barbara
B
Hartleb
Marek
M
D000752:Anemia, Pernicious / Q000139:chemically induced*; D000998:Antiviral Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b